BS_CS170P7T
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 110.80814717477003
- age_years
- 9.088
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.614
- INTERFERON_GAMMA_RESPONSE+0.578
- ALLOGRAFT_REJECTION+0.453
- IL6_JAK_STAT3_SIGNALING+0.438
- TNFA_SIGNALING_VIA_NFKB+0.403
- INFLAMMATORY_RESPONSE+0.371
- COMPLEMENT+0.259
- IL2_STAT5_SIGNALING+0.242
- KRAS_SIGNALING_UP+0.229
- TGF_BETA_SIGNALING+0.205
Top 10 suppressed
- MYC_TARGETS_V1-0.480
- E2F_TARGETS-0.437
- MYC_TARGETS_V2-0.412
- G2M_CHECKPOINT-0.405
- OXIDATIVE_PHOSPHORYLATION-0.401
- CHOLESTEROL_HOMEOSTASIS-0.330
- DNA_REPAIR-0.312
- MTORC1_SIGNALING-0.298
- SPERMATOGENESIS-0.278
- GLYCOLYSIS-0.267
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20030005.Her2HRpos | — | A | 0.918 |
| 2 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.905 |
| 3 | BS_25T139TX | low-grade glioma | — | 0.898 |
| 4 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.895 |
| 5 | DRR168552 | — | — | 0.888 |
| 6 | DRR168509 | — | — | 0.887 |
| 7 | TCGA-MP-A4TJ-01A-51R-A262-07 | — | cohortA1 | 0.885 |
| 8 | TCGA-CN-6013-01A-11R-1686-07 | — | — | 0.883 |
| 9 | GSM5359418 | — | — | 0.879 |
| 10 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.614 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.578 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.453 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.438 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.403 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.371 | Idelalisib | — uncovered |
| COMPLEMENT | 0.259 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.242 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.229 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.205 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.185 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.183 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.175 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.142 | Inavolisib | — uncovered |
| COAGULATION | 0.124 | Binimetinib | — uncovered |
| APOPTOSIS | 0.107 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.105 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.054 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.043 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.025 | Inavolisib | — uncovered |